Trial Profile

A Norwegian Study of Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication Within Rheumatology and Gastroenterology: the Nor-vaC Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2024 Results (n=371) assessing neutralizing capacity and serologic responses to SARS-CoV-2 in TNFi-treated IMID patients, after receiving a monovalent 4th vaccine dose and a bivalent 5th vaccine dose, including those with hybrid immunity presented at the 25th Annual Congress of the European League Against Rheumatism
15 Nov 2023 Results (n=144) assessing longitudinal T cell responses across diagnoses, following vaccine series and COVID-19 in patients on tumor necrosis factor inhibitors, presented at the ACR Convergence 2023.
15 Nov 2023 Results (n=243) assessing vaccine responses in patients with immune mediated inflammatory diseases using immunosuppressive therapies, presented at the ACR Convergence 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com